Debiopharm a Swiss biopharmaceutical company, announced today the first patient dosed in their phase III clinical trial (TrilynX) with xevinapant, an orally available antagonist of IAPs cancer therapy in combination with CRT for LA-SCCHN patients. This prospective, randomized, double-blind, placebo-controlled, multicenter, 2-arm clinical trial is being conducted to demonstrate the superior efficacy of xevinapant vs. placebo when added to CRT in high-risk head and neck patients including those affected in the throat and vocal chords (oropharynx -HPV-negative, hypopharynx and larynx). The TrilynX study is being launched worldwide in 25 countries in over 200 sites with the aim of enrolling approximately 700 patients. Yourway is fully ready to support global clinical trials.